B-Cell Chronic Lymphocytic Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

B Cell Chronic Lymphocytic Leukemia Pipeline Drugs Market Overview

B-Cell Chronic Lymphocytic Leukemia pipeline market research report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.

Key Targets in the B-Cell Chronic Lymphocytic Leukemia Pipeline Market

The key targets in the B-Cell Chronic Lymphocytic Leukemia pipeline market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK, CD3, Tyrosine Protein Kinase SYK, Apoptosis Regulator Bcl 2, B Cell Lymphoma 2, B Lymphocyte Antigen CD20, Cells Expressing B Cell Receptor CD22, and Cells Expressing CAMPATH 1 Antigen. Cells Expressing B Lymphocyte Antigen CD19 has the highest number of pipeline products.

B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by Targets

B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by Targets

For more target insights, download a free report sample

Types of MoA in the B-Cell Chronic Lymphocytic Leukemia Pipeline Market

The types of key MoA in the B-Cell Chronic Lymphocytic Leukemia pipeline market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK Inhibitor, CD3 Agonist, Tyrosine Protein Kinase SYK Inhibitor, Apoptosis Regulator Bcl 2 Inhibitor, B Cell Lymphoma 2 Inhibitor, B Lymphocyte Antigen CD20 Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, and Cytotoxic To Cells Expressing CAMPATH 1 Antigen. Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19 has the maximum number of pipeline products.

B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by MoA

B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by MoA

For more MoA insights, download a free report sample

Types of RoA in the B-Cell Chronic Lymphocytic Leukemia Pipeline Market

The key routes of administration in the B-Cell Chronic Lymphocytic Leukemia pipeline market are intravenous, oral, parenteral, intravenous drip, ophthalmic, subcutaneous, and topical. Intravenous has the majority number of pipeline products.

B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by RoA

B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the B-Cell Chronic Lymphocytic Leukemia Pipeline Market

The key molecule types in the B-Cell Chronic Lymphocytic Leukemia pipeline market are gene-modified cell therapy, small molecule, monoclonal antibody, and monoclonal antibody conjugated. Gene-modified cell therapy has the highest number of pipeline products.

B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by Molecule Type

B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by Molecule Type

For more molecule type insights, download a free report sample

Key Companies in the B-Cell Chronic Lymphocytic Leukemia Pipeline Market

The key companies in the B Cell Chronic Lymphocytic Leukemia pipeline drugs market are BeiGene Ltd, Bristol-Myers Squibb Co, iDD biotech SAS, Loxo Oncology Inc, AB Science SA, Alexion Pharmaceuticals Inc, and Beijing Immunochina Pharmaceuticals Co Ltd. BeiGene Ltd has the highest number of pipeline products.

AB Science SA: AB Science SA (ABS) is a pharmaceutical company focused on the discovery, development, and commercialization of protein kinase inhibitors. The company’s lead compound Masitinib is an orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, and Lyn in several human indications such as oncology, inflammatory diseases, and central nervous system diseases. AB Science has developed several medicines for humans, ongoing phase 2 and phase 3 studies in oncology and non-oncology diseases. The company is commercializing its lead product candidate in human and veterinary medicine. It has operations in France and the US. ABS is headquartered in Paris, France.

B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by Companies

B-Cell Chronic Lymphocytic Leukemia Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK, CD3, Tyrosine Protein Kinase SYK, Apoptosis Regulator Bcl 2, B Cell Lymphoma 2, B Lymphocyte Antigen CD20, Cells Expressing B Cell Receptor CD22, and Cells Expressing CAMPATH 1 Antigen
Key MoA Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK Inhibitor, CD3 Agonist, Tyrosine Protein Kinase SYK Inhibitor, Apoptosis Regulator Bcl 2 Inhibitor, B Cell Lymphoma 2 Inhibitor, B Lymphocyte Antigen CD20 Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, and Cytotoxic To Cells Expressing CAMPATH 1 Antigen
Key RoA Intravenous, Oral, Parenteral, Intravenous Drip, Ophthalmic, Subcutaneous, and Topical
Key molecule types Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, and Monoclonal Antibody Conjugated
Key companies BeiGene Ltd, Bristol-Myers Squibb Co, iDD biotech SAS, Loxo Oncology Inc, AB Science SA, Alexion Pharmaceuticals Inc, and Beijing Immunochina Pharmaceuticals Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

AB Science SA
Alexion Pharmaceuticals Inc
BeiGene Ltd
Beijing Immunochina Pharmaceuticals Co Ltd
BioIntegrator
BioInvent International AB
Biosplice Therapeutics Inc
BioXpress Therapeutics SA
Bristol-Myers Squibb Co
Chengdu USino Technology Biology Co Ltd
CRISPR Therapeutics AG
Eisai Co Ltd
Hangzhou Hezheng Pharmaceutical Co Ltd
iDD biotech SAS
Kuur Therapeutics Ltd
Loxo Oncology Inc
Mediolanum farmaceutici SpA
Merck & Co Inc
Nkarta Inc
Nordic Nanovector ASA
Regeneron Pharmaceuticals Inc
Shanghai Pharmaceutical Group Co Ltd
Tianweiyuan and Biomedicine Shanghai Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

B-Cell Chronic Lymphocytic Leukemia – Overview

B-Cell Chronic Lymphocytic Leukemia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

B-Cell Chronic Lymphocytic Leukemia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

B-Cell Chronic Lymphocytic Leukemia – Companies Involved in Therapeutics Development

B-Cell Chronic Lymphocytic Leukemia – Drug Profiles

B-Cell Chronic Lymphocytic Leukemia – Dormant Projects

B-Cell Chronic Lymphocytic Leukemia – Discontinued Products

B-Cell Chronic Lymphocytic Leukemia – Product Development Milestones

Featured News & Press Releases

Feb 03, 2020: Calibr’s ‘switchable’ CAR-T platform for cancer moves forward with FDA clearance of Investigational New Drug application

Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by AB Science SA, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Alexion Pharmaceuticals Inc, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by BeiGene Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Beijing Immunochina Pharmaceuticals Co Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by BioIntegrator, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by BioInvent International AB, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Biosplice Therapeutics Inc, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by BioXpress Therapeutics SA, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Bristol-Myers Squibb Co, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Chengdu USino Technology Biology Co Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by CRISPR Therapeutics AG, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Eisai Co Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Hangzhou Hezheng Pharmaceutical Co Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by iDD biotech SAS, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Kuur Therapeutics Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Loxo Oncology Inc, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Mediolanum farmaceutici SpA, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Merck & Co Inc, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Nkarta Inc, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Nordic Nanovector ASA, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Regeneron Pharmaceuticals Inc, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Pipeline by Tianweiyuan and Biomedicine Shanghai Co Ltd, 2022

B-Cell Chronic Lymphocytic Leukemia – Dormant Projects, 2022

B-Cell Chronic Lymphocytic Leukemia – Dormant Projects, 2022 (Contd..1)

B-Cell Chronic Lymphocytic Leukemia – Dormant Projects, 2022 (Contd..2)

B-Cell Chronic Lymphocytic Leukemia – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

B-Cell Chronic Lymphocytic Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at B-Cell Chronic Lymphocytic Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live B-Cell Chronic Lymphocytic Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.